| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 0 | 211 | 525 | 0 | 0 | 0 | 0 |
| Total Income - EUR | - | - | - | 0 | 3.509 | 5.596 | 0 | 0 | 0 | 27 |
| Total Expenses - EUR | - | - | - | 587 | 9.650 | 5.013 | 86 | 68 | 994 | 894 |
| Gross Profit/Loss - EUR | - | - | - | -587 | -6.140 | 583 | -86 | -68 | -994 | -867 |
| Net Profit/Loss - EUR | - | - | - | -587 | -6.142 | 572 | -86 | -68 | -994 | -867 |
| Employees | - | - | - | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Mybiosyl S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 35 | 0 | 30 | 0 | 0 | 9.904 | 12.279 |
| Current Assets | - | - | - | 65 | 5.593 | 6.652 | 6.447 | 6.399 | 6.000 | 5.119 |
| Inventories | - | - | - | 0 | 3.752 | 3.632 | 3.551 | 3.562 | 3.551 | 4.558 |
| Receivables | - | - | - | 0 | 94 | 38 | 37 | 38 | 336 | 395 |
| Cash | - | - | - | 65 | 1.747 | 2.982 | 2.859 | 2.800 | 2.113 | 166 |
| Shareholders Funds | - | - | - | -544 | -6.676 | -5.977 | -5.931 | -6.017 | -6.993 | -7.822 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 645 | 12.270 | 12.659 | 12.379 | 12.417 | 22.898 | 25.219 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "1629 - 1629" | |||||||||
| CAEN Financial Year |
1629
|
|||||||||
Comments - Mybiosyl S.r.l.